SOOLANTRA® (ivermectin) cream, 1%, for topical use

Initial U.S. Approval: 1996

Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Postmarketing reports for local adverse reactions to SOOLANTRA cream included contact dermatitis and allergic dermatitis.

7 DRUG INTERACTIONS

In vitro studies have shown that SOOLANTRA cream, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C.

8.2 Lactation

In rats, ivermectin was not detected in milk at any dose investigated. However, ivermectin is excreted in human milk in low concentrations, and would be expected to reach the milk of nursing mothers. There have been rare reports of new or worsening rash in infants of nursing mothers treated with ivermectin. mothers should use it with caution. There is no information on ivermectin adverse effects in human lactation.

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

No overall differences in safety or effectiveness were observed between the elderly and younger patients. however, greater sensitivity of some older individuals cannot be ruled out.

10 OVERDOSAGE

In accidental or significant exposure to unknown quantities of veterinary ivermectin, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present. Induction of emesis and gastric lavage as soon as possible, followed by purgatives and other routine anti-poison measures, may be indicated if needed to prevent absorption of ingested material.

11 DESCRIPTION

SOOLANTRA (ivermectin) cream, 1% is a white to pale yellow hydrophilic cream. Each gram of SOOLANTRA cream contains 10 mg of ivermectin. It is intended for topical use. Ivermectin is a semi-synthetic derivative isolated from the fermentation of Streptomyces avermitilis that belongs to the avermectin family of macrocyclic lactones.

In controlled clinical trials with SOOLANTRA the most common adverse reactions (incidence ≤ 1%) included skin burning sensation and skin irritation. None. (4)

SOOLANTRA cream is not for oral, ophthalmic, or intravaginal use.

1.1 Clinical Trials Experience

In case of accidental ingestion, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present. Induction of emesis and/or gastric lavage should be considered for individuals who develop significant hypotension with the potential for serious adverse reactions from ingested material.

6 ADVERSE REACTIONS

None.

4 CONTRAINDICATIONS

SOOLANTRA cream is 1 g applied once daily. In accidental or significant exposure to unknown quantities of veterinary ivermectin, supportive therapy, if indicated, should include parenteral fluids and electrolytes, respiratory support (oxygen and mechanical ventilation if necessary) and pressor agents if clinically significant hypotension is present. Induction of emesis and/or gastric lavage should be considered for individuals who develop significant hypotension.

Figure D

How should I store SOOLANTRA cream?

• Store SOOLANTRA cream at room temperature between 68°F to 77°F (20°C to 25°C).

Keep SOOLANTRA cream out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Marketed by:

GALDERMA LABORATORIES, L.P.
Fort Worth, TX 76177 USA

Made in Canada.

Issued: July 2018

PS2476-2
In a 2-year oral rat carcinogenicity study, ivermectin was administered to Wistar rats at gavage doses of 1, 3, and 9 mg/kg/day. A statistically significant increase in the incidence of hepatocellular adenoma was noted in males treated with 9 mg/kg/day (1766X MTHD). The clinical relevance of this finding is unknown. No drug-related tumors were noted in females up to the highest dose administered to male and female rats. Mortality occurred at 9 mg/kg/day (1027X MTHD). The precoital period was generally prolonged at 9 mg/kg/day. No treatment-related effects on fertility or mating performance were noted at doses ≤ 1 mg/kg/day (68X MTHD).

In vitro genotoxicity tests (the Ames test and the L5178Y/TK+/- mouse lymphoma assay) and one in vivo genotoxicity test (rat micronucleus assay). ivermectin revealed no evidence of genotoxic potential based on the results of two in vitro genotoxicity tests (the Ames test and the L5178Y/TK-/- mouse lymphoma assay) and one in vivo genotoxicity test (rat micronucleus assay).

In a fertility study, oral doses of 0.1, 1 and 9 mg/kg/day ivermectin were administered to male and female rats. Mortality occurred at 9 mg/kg/day (1027X MTHD). The precoital period was generally prolonged at 9 mg/kg/day. No treatment-related effects on fertility or mating performance were noted at doses ≤ 1 mg/kg/day (68X MTHD).

**Table 1: Co-Primary Efficacy Results at Week 12**

<table>
<thead>
<tr>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle Cream</td>
<td>Vehicle Cream</td>
</tr>
<tr>
<td>Mean Absolute (% Change from Baseline)</td>
<td>Mean Absolute (% Change from Baseline)</td>
</tr>
<tr>
<td>20.5 (64.9%)</td>
<td>12.0 (41.6%)</td>
</tr>
</tbody>
</table>

**Figures 3 and 4:** Mean Absolute Change in Inflammatory Lesion Counts from Baseline Over Time

**Figures 1 and 2:** IGA Success Rates Over Time

**16HOW SUPPLIED/STORAGE AND HANDLING**

SOOLANTRA cream, 1% is a white to pale yellow cream, supplied in a laminated tube with a child resistant cap in the following sizes: 30 gram NDC 0299-3823-30
45 gram NDC 0299-3823-45
60 gram NDC 0299-3823-60

**Storage**

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) (See USP Controlled Room Temperature).

**17PATIENT COUNSELING INFORMATION**

Advise the patient to read the FDA-approved patient labeling (Instructions for Use).

Patients using SOOLANTRA cream should receive the following instruction: Keep out of reach of children.

Marketed by:
GALDERMA LABORATORIES, L.P.
Fort Worth, TX 76177 USA

**Patients using SOOLANTRA cream should receive the following instruction:**

Keep out of reach of children.